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Chronic	  pain	  accompanies	  many	  diseases	  and	  conditions.	  The	  molecular	  pathways	  transmitting	  
pain	  are	  not	  completely	  understood.	  Investigating	  the	  mechanisms	  at	  the	  pre-­‐synapse	  has	  revealed	  
involvement	  of	  P2X3	  receptors	  and	  calcium-­‐dependent	  scaffolding	  protein	  kinases	  (CASK).	  While	  
involvement	  of	  these	  two	  molecules	  and	  their	  interaction	  have	  been	  described	  in	  pain	  transmission	  in	  
rats,	  much	  less	  is	  known	  about	  the	  existence	  of	  this	  interaction	  in	  humans.	  This	  was	  the	  aim	  of	  our	  
studies.	  Through	  overexpression	  of	  human	  P2X3	  and	  CASK	  in	  HEK	  cells,	  co-­‐immunoprecipitation,	  
Western	  blotting,	  and	  immunostaining	  techniques,	  we	  studied	  the	  P2X3	  and	  CASK	  interaction,	  focusing	  
on	  the	  receptor	  C-­‐terminal	  sequences.	  Overexpression	  of	  P2X3	  and	  CASK	  was	  stable	  along	  with	  protein	  
subcellular	  co-­‐localization.	  CASK	  proteins	  were	  pulled	  down	  with	  human	  P2X3	  receptors	  verifying	  an	  
interaction.	  The	  mechanism	  of	  interaction	  remains	  under	  investigation	  and	  is	  a	  new	  target	  for	  the	  
development	  of	  pain	  relief	  medication. 
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1.	  Introduction	  
Chronic	  pain	  has	  become	  an	  increasing	  problem	  worldwide	  and	  impacts	  over	  1.5	  billion	  people	  
(“Global	  Pain,”	  2011).	  Chronic	  pain	  is	  diagnosed	  as	  pain	  that	  can	  span	  from	  inconvenient	  to	  extreme,	  
either	  continuous	  or	  periodic,	  and	  lasts	  longer	  than	  six	  months.	  It	  is	  difficult	  to	  treat	  chronic	  pain	  due	  to	  
the	  symptoms	  experienced	  by	  the	  individual,	  ranging	  from	  aching,	  sharp,	  or	  throbbing	  feelings	  to	  
burning,	  tingling,	  stabbing,	  or	  the	  pins	  and	  needles	  sensation	  (“Types	  of	  Pain,”	  2007).	  Pain	  severity	  is	  
arbitrary	  and	  complicated	  to	  quantify	  because	  everyone	  registers	  pain	  differently	  (“Evaluation	  of	  Pain,”	  
2007).	  
Because	  chronic	  pain	  is	  intricate	  and	  the	  pain	  pathways	  are	  not	  fully	  understood,	  
pharmaceutical	  companies	  have	  created	  general	  medications	  to	  regulate	  pain	  by	  attempting	  to	  
subsidize	  the	  symptoms,	  rather	  than	  blocking	  the	  pathways	  involved.	  Medications	  such	  as	  Vicodin	  and	  
Percocet	  have	  been	  created	  that	  contain	  either	  hydrocodone	  or	  oxycodone,	  both	  of	  which	  are	  opioids.	  
Opioids	  are	  a	  group	  of	  compounds	  that	  bind	  to	  opiate	  receptors,	  mostly	  located	  in	  the	  brain,	  and	  are	  
known	  for	  decreasing	  pain	  severity	  for	  the	  patient	  (“What	  are	  Opioids?,”	  2011).	  These	  drugs	  are	  mainly	  
to	  treat	  chronic	  pain,	  while	  Ibuprofen	  and	  Tylenol	  are	  medications	  that	  are	  used	  to	  treat	  acute	  pain,	  
which	  is	  pain	  that	  lasts	  only	  a	  short	  period	  of	  time	  before	  subsiding	  (“Prescription	  Drug	  Abuse,”	  n.d.).	  
Unfortunately,	  these	  medications	  have	  led	  to	  many	  problems	  such	  as	  addiction	  and	  drug	  
efficacy.	  Even	  though	  opioids	  have	  the	  potential	  in	  minimizing	  pain	  that	  people	  experience,	  there	  is	  a	  
high	  risk	  of	  addiction	  to	  these	  drugs	  because	  of	  the	  euphoric	  effect	  that	  is	  caused	  by	  the	  flood	  of	  
dopamine	  and	  serotonin	  in	  the	  brain.	  In	  addition	  to	  this,	  the	  body	  becomes	  desensitized	  to	  the	  drug	  
after	  several	  doses	  of	  the	  same	  amount,	  so	  the	  amount	  must	  be	  increased	  in	  order	  to	  achieve	  the	  same	  
efficacy	  (Dugdale,	  2010).	  Based	  on	  these	  reasons,	  further	  research	  should	  develop	  a	  novel	  way	  to	  treat	  
pain	  rather	  than	  relying	  on	  medications	  with	  a	  chance	  of	  drug	  dependency.	  
There	  have	  been	  strides	  in	  understanding	  the	  molecular	  mechanisms	  of	  the	  sensitization	  in	  pain	  
pathways	  in	  order	  to	  treat	  the	  source	  of	  pain,	  instead	  of	  the	  symptoms.	  We	  analyzed	  a	  specific	  
purinergic	  receptor	  called	  P2X3,	  which	  is	  believed	  to	  have	  a	  modulatory	  role	  in	  transduction	  of	  pain	  
stimuli	  and	  in	  chronic	  pain	  progression.	  Another	  component	  arguably	  related	  to	  P2X3	  is	  
calcium/calmodulin-­‐dependent	  serine	  kinase	  (CASK),	  which	  was	  recently	  identified	  as	  a	  novel	  scaffold	  
protein	  kinase	  that	  co-­‐localizes	  with	  P2X3	  (Gnanasekaran	  et	  al.,	  2013).	  However,	  the	  P2X3/CASK	  
complex	  is	  still	  not	  completely	  understood,	  especially	  regarding	  the	  nature	  of	  the	  interaction	  and	  any	  
molecular	  and	  structural	  determinants	  that	  regulate	  the	  complex.	  Despite	  the	  homology,	  significant	  
differences	  have	  been	  observed	  between	  human	  and	  rat	  P2X3	  receptors	  (Sundukova	  et	  al.,	  2012),	  
therefore	  it	  is	  necessary	  to	  confirm	  the	  P2X3	  receptor	  and	  CASK	  protein	  complex	  with	  the	  human	  
receptor.	  
At	  the	  Center	  for	  Biomedical	  Sciences	  and	  Engineering	  at	  the	  University	  of	  Nova	  Gorica,	  we	  
researched	  the	  P2X3	  receptor	  and	  CASK	  protein,	  their	  interaction,	  and	  differences	  found	  between	  
human	  and	  rat	  P2X3	  sequences	  in	  relation	  to	  CASK.	  P2X3’s	  modulation	  and	  control	  to	  suppress	  pain	  
signals	  hold	  potential	  for	  the	  development	  of	  novel	  pain	  relief	  medications.	  
	   	  
2.	  Background	  
2.1	  Chronic	  Pain	  Pathways	  
Pain	  can	  be	  distinguished	  into	  two	  different	  types:	  acute	  and	  chronic.	  Acute	  pain	  is	  defined	  as	  a	  
sharp,	  quick	  pain	  that	  is	  felt	  when	  the	  body	  is	  injured	  and	  then	  subsides	  after	  the	  injury	  is	  healed.	  
Chronic	  pain	  can	  be	  divided	  into	  many	  different	  sections	  due	  to	  its	  complexity	  in	  area,	  severity,	  and	  
persistence.	  Chronic	  pain	  can	  turn	  into	  neuropathic	  pain	  if	  damage	  or	  dysfunction	  of	  nervous	  structures	  
is	  observed	  and	  the	  pain	  inhibitory	  pathway	  is	  much	  weaker	  as	  well.	  When	  a	  painful	  stimulus	  is	  felt	  by	  
nociceptive	  receptors	  found	  in	  the	  skin,	  the	  pathway	  to	  the	  brain	  is	  extremely	  similar	  in	  both	  cases	  (Hall,	  
2010).	  
When	  the	  body	  receives	  a	  stimulus	  from	  sensory	  receptors	  found	  in	  the	  skin,	  open	  nerve	  
endings	  are	  activated.	  This	  creates	  a	  cascade	  of	  impulses	  throughout	  the	  peripheral	  nervous	  system	  
(PNS)	  and	  central	  nervous	  system	  (CNS).	  The	  sensory	  neurons,	  also	  called	  Aδ-­‐	  and	  C-­‐fibers,	  transmit	  the	  
signal	  towards	  the	  ganglia	  with	  different	  speeds	  due	  to	  thin	  or	  poorly	  myelinated	  fibers	  (Weiss	  et	  al.,	  
2008).	  After	  passing	  the	  ganglion,	  the	  impulse	  enters	  the	  dorsal	  horn	  of	  the	  spinal	  cord	  where	  synapse	  
interactions	  occur.	  Presynaptic	  voltage-­‐gated	  calcium	  channels	  release	  vesicles	  containing	  glutamate	  
into	  the	  synapse	  to	  activate	  the	  postsynaptic	  neuron	  via	  N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	  receptors.	  This	  
occurs	  until	  the	  signal	  is	  relayed	  to	  the	  thalamus	  in	  the	  lower	  brainstem,	  which	  can	  then	  be	  transmitted	  
to	  the	  sensory	  and	  motor	  cortices	  or	  the	  hypothalamus.	  From	  there,	  the	  sensation	  of	  pain	  is	  felt	  by	  the	  
individual	  and	  either	  a	  motor	  or	  emotional	  response	  occurs.	  
Individual	  differences	  in	  the	  pain	  threshold	  can	  occur	  at	  the	  different	  neuronal	  levels,	  PNS	  or	  
CNS.	  A	  motor	  response	  occurs	  within	  the	  spinal	  cord,	  without	  reaching	  the	  upper	  central	  neuronal	  
components,	  and	  allows	  the	  individual	  to	  move	  away	  from	  the	  painful	  stimuli.	  Emotional	  responses	  
occur	  when	  the	  signal	  is	  passed	  into	  the	  hypothalamus.	  Overall,	  once	  the	  stimulus	  begins,	  the	  pathway	  
occurs	  instantaneously	  (Hall,	  2010).	  Figure	  2-­‐1	  below	  shows	  this	  pre-­‐	  and	  post-­‐synaptic	  interaction.	  
	  
	  
Figure	  2-­‐1:	  Pre	  and	  Postsynaptic	  Interaction	  
	  
Additionally,	  there	  are	  also	  other	  ligand-­‐	  and	  voltage-­‐gated	  channels,	  including	  purinergic	  
receptors,	  which	  are	  present	  in	  the	  periphery	  and	  synapse	  that	  facilitate	  in	  transferring	  the	  pain	  signal.	  
2.2	  Current	  Trends	  in	  Pain	  Medication	  
Over-­‐the-­‐counter	  analgesic	  drugs,	  or	  OTCs,	  are	  non-­‐prescription	  drugs	  that	  are	  used	  to	  treat	  
different	  types	  of	  pain.	  The	  market	  for	  analgesic	  drugs	  has	  become	  present	  over	  the	  years	  with	  the	  
increase	  of	  drug	  use	  in	  the	  population.	  Among	  these	  sorts	  of	  drugs	  are	  NSAIDs,	  or	  nonsteroidal	  anti-­‐
inflammatory	  drugs,	  which	  are	  also	  antipyretic,	  or	  fever-­‐reducing.	  Some	  of	  the	  most	  effective	  NSAIDs	  
known	  include	  aspirin	  and	  ibuprofen.	  This	  class	  of	  drugs	  is	  a	  safe,	  common,	  and	  inexpensive	  alternative	  
to	  many	  pain	  medications	  (Abbott	  &	  Fraser,	  1998).	  
	   NSAIDs	  work	  by	  inhibiting	  enzymatic	  activity	  that	  participates	  in	  physiological	  processes	  of	  the	  
PNS	  and	  CNS.	  COX	  1,	  or	  cyclooxygenase	  1,	  and	  COX	  2	  are	  involved	  in	  the	  synthesis	  of	  prostaglandins,	  
which	  can	  be	  autocrine	  or	  paracrine	  hormones.	  COX	  1	  is	  normally	  expressed	  in	  many	  tissues	  in	  the	  
human	  body,	  while	  COX	  2	  is	  expressed	  in	  the	  presence	  of	  inflamed	  tissues,	  which	  accounts	  for	  redness	  in	  
inflamed	  tissue	  regions.	  NSAIDs	  inhibit	  this	  action	  as	  antagonists,	  inhibiting	  the	  production	  of	  
prostaglandins,	  thereby	  reducing	  redness	  and	  inflammation	  (Abbott	  &	  Fraser,	  1998).	  
	   Opioids	  are	  a	  class	  of	  prescription	  analgesic	  drugs	  that	  have	  become	  generally	  used	  by	  the	  
population.	  The	  most	  popular	  opioid	  is	  morphine,	  an	  alkaloid	  that	  originates	  from	  the	  juice	  of	  the	  poppy	  
flower.	  Other	  opioids	  are	  naturally	  occurring	  and	  can	  be	  harvested,	  such	  as	  morphine.	  Opioids	  are	  
mostly	  administered	  orally,	  but	  can	  also	  be	  introduced	  intravenously,	  subcutaneously,	  nasally,	  and	  
through	  epidural	  means.	  Despite	  these	  modes	  of	  administration,	  their	  mechanism	  of	  action	  is	  the	  same	  
(Schäfer,	  2010).	  
	   Analgesic	  opioids,	  such	  as	  morphine	  and	  codeine,	  work	  by	  reducing	  neuronal	  excitement.	  This	  
excitement	  is	  indicative	  of	  a	  pain	  signal,	  and	  they	  are	  defined	  as	  full	  opioid	  agonists,	  a	  term	  reserved	  for	  
compounds	  that	  activate	  opioid	  receptors.	  Opioid	  receptors	  are	  a	  family	  of	  receptors	  that	  signal	  neurons	  
to	  decrease	  the	  pain	  signal.	  The	  signal	  is	  usually	  minimized	  in	  the	  presence	  of	  endogenous	  opioids	  and	  
takes	  the	  form	  of	  peptides	  which	  bind	  and	  activate	  the	  opioid	  receptors.	  Through	  the	  use	  of	  these	  
agonists,	  the	  pain	  signal	  is	  decreased	  and	  pain	  is	  inhibited.	  This	  is	  their	  primary	  mechanism	  of	  action,	  yet	  
nearly	  all	  drugs	  contain	  side	  effects.	  Side	  effects	  of	  opioid	  users	  include	  sedation	  and	  nausea	  (Schäfer,	  
2010).	  
	   Despite	  the	  efficacy	  of	  these	  two	  classes	  of	  drugs,	  they	  come	  with	  their	  disadvantages.	  NSAIDs,	  
while	  lacking	  addictive	  properties,	  can	  be	  abused	  very	  easily.	  Since	  OTCs	  are	  available	  in	  supermarkets,	  
drug	  stores,	  and	  pharmacies,	  they	  are	  available	  to	  the	  general	  population	  without	  prescription.	  Drug	  
abuse,	  which	  may	  come	  with	  a	  lack	  of	  the	  effects	  of	  overdose	  and	  prolonged	  use,	  is	  a	  widespread	  and	  
challenging	  problem	  that	  pharmacologists	  continue	  to	  tackle	  today.	  Perhaps	  the	  most	  destructive	  
somatic	  disease	  that	  related	  to	  prolonged	  NSAID	  abuse	  is	  analgesic	  nephropathy,	  a	  kidney	  disease	  
(Vadivel	  et	  al.,	  2006).	  Opioids	  are	  also	  addictive	  compounds	  due	  to	  their	  narcotic	  properties.	  Over	  time,	  
those	  with	  prescriptions	  for	  opioids,	  such	  as	  hydrocodone	  or	  dihydrocodeine,	  may	  develop	  
dependencies	  which	  can	  lead	  to	  full	  blown	  addictions	  (Veilleux	  et	  al.,	  2010).	  While	  these	  drugs	  do	  satisfy	  
those	  suffering	  from	  pain,	  the	  side	  effects	  and	  risks	  still	  pose	  dangers.	  These	  drugs	  minimize	  the	  pain	  
signal	  by	  nullifying	  neuronal	  excitement	  and	  impairing	  production	  of	  prostaglandins,	  yet	  do	  not	  directly	  
inhibit	  the	  pain	  signal.	  Further	  research	  of	  the	  molecules	  and	  mechanisms	  that	  direct	  the	  pain	  signal	  
ought	  to	  be	  a	  priority,	  rather	  than	  searching	  for	  new	  methods	  to	  avoid	  the	  onset	  of	  nephropathy	  or	  
narcotic	  addictions.	  
2.3	  Purinergic	  Receptors	  
Purinergic	  receptors,	  also	  named	  purinoceptors,	  are	  located	  in	  the	  plasma	  membrane	  and	  are	  
known	  to	  be	  participants	  in	  many	  organism	  functions	  such	  as	  learning,	  locomotion,	  and	  feeding	  
behavior.	  In	  addition,	  purinergic	  receptors	  have	  specific	  cellular	  functions	  such	  as	  proliferation	  and	  
migration	  of	  neural	  stem	  cells,	  changes	  in	  blood	  vessels,	  apoptosis,	  and	  cytokine	  secretion	  (Burnstock,	  
2013).	  These	  receptors	  are	  active	  in	  a	  wide	  range	  of	  roles	  in	  the	  body.	  
Purinergic	  receptors	  include	  the	  P1	  and	  P2	  classes.	  The	  P1	  family	  contains	  adenosine	  receptors	  
and	  the	  P2	  family	  contains	  P2X	  and	  P2Y	  subfamilies.	  The	  latter	  family	  provides	  affinities	  only	  for	  
nucleosides.	  P2Y	  receptors	  have	  a	  slight	  affinity	  for	  adenosine	  triphosphate	  nucleoside	  (ATP),	  but	  accept	  
uracil	  triphosphate	  nucleoside,	  uracil	  diphosphate	  nucleoside	  (UDP),	  UDP-­‐glucose,	  and	  adenosine	  
diphosphate	  nucleoside	  as	  well.	  The	  P2X	  family	  binds	  to	  ATP	  with	  different	  affinities,	  from	  nM	  for	  P2X3	  
to	  mM	  ATP	  concentrations	  for	  P2X7	  receptors	  (Jellinger,	  2003).	  
2.3.1	  P2X	  Receptors	  
P2X	  receptors	  are	  not	  found	  solely	  in	  mammals,	  but	  also	  in	  other	  organisms	  such	  as	  amoebas	  
and	  zebrafish.	  They	  are	  ATP	  ligand-­‐gated	  ion	  channels,	  meaning	  the	  presence	  of	  ATP	  opens	  the	  channel	  
which	  subsequently	  regulates	  the	  passage	  of	  ions.	  Each	  P2X	  receptor	  consists	  of	  three	  subunits	  and	  each	  
subunit	  is	  formed	  by	  two	  domains	  spanning	  the	  plasma	  membrane,	  a	  large	  extracellular	  loop,	  and	  
intracellular	  carboxyl	  and	  amino	  termini.	  Multimers	  of	  P2X	  subunits,	  either	  homomeric	  or	  heteromeric,	  
create	  the	  ion	  channels	  and	  different	  receptor	  subtypes	  are	  expressed	  in	  different	  tissues.	  In	  particular,	  
homotrimeric	  P2X3	  is	  being	  researched	  for	  its	  importance	  in	  pain,	  especially	  in	  chronic	  pain	  because	  the	  
P2X3	  receptor	  is	  highly	  expressed	  in	  sensory	  fibers	  (North,	  2002).	  
2.3.2	  P2X3	  Receptor	  
Of	  the	  seven	  P2X	  receptors,	  P2X3	  is	  suggested	  to	  be	  involved	  in	  pain	  transduction	  in	  sensory	  
neurons.	  These	  receptors	  are	  specifically	  found	  on	  the	  pre-­‐synapse	  in	  C-­‐fiber	  afferent	  sensory	  neurons	  
(Ford,	  2012).	  Extracellular	  ATP	  rapidly	  activates	  the	  extracellular	  domain	  of	  P2X3	  receptors,	  which	  are	  
sensitive	  to	  nanomolar	  ATP	  concentrations,	  inducing	  an	  ion	  channel	  to	  form	  between	  three	  subunits.	  
Calcium,	  potassium,	  and	  sodium	  flow	  through	  the	  non-­‐specific	  channel	  and	  the	  resulting	  action	  
potentials	  are	  interpreted	  as	  pain	  (Fabbretti	  &	  Nistri,	  2012).	  
Researchers	  looked	  to	  identify	  negatively-­‐charged	  residues	  owing	  to	  the	  extracellular	  activation	  
of	  P2X3	  receptors	  in	  the	  presence	  of	  the	  P2X3-­‐specific	  agonist,	  alpha,beta-­‐methylene-­‐ATP	  (α,β-­‐meATP),	  
which	  is	  more	  stable	  than	  ATP	  and	  not	  hydrolysable.	  The	  use	  of	  this	  agonist,	  which	  induced	  enzymatic	  
activity	  with	  an	  artificial	  molecule,	  rapidly	  desensitized	  P2X3.	  However,	  when	  Ca2+	  flooded	  the	  
extracellular	  domain,	  P2X3	  receptors	  regained	  potential	  to	  activate	  in	  the	  presence	  of	  ATP.	  They	  found	  
that	  P2X3	  receptors	  rapidly	  activate	  and	  recover	  in	  the	  presence	  of	  high	  levels	  of	  extracellular	  Ca2+	  
(Fabbretti	  et	  al.,	  2004).	  
Recent	  advances	  have	  shown	  that	  human	  and	  murine	  P2X3	  receptors	  differ	  in	  activity	  based	  on	  
the	  phosphorylation	  state	  in	  C-­‐terminus	  residues	  (Sundukova	  et	  al.,	  2012).	  
2.3.3	  Comparison	  of	  Human	  and	  Rat	  P2X3	  Sequences	  
Human	  and	  rat	  P2X3	  sequences	  are	  extremely	  similar	  with	  their	  amino	  acid	  sequences	  being	  
97%	  identical	  (Garcia-­‐Guzman	  et	  al.,	  1997).	  Focusing	  on	  the	  intracellular	  C-­‐terminal	  region,	  there	  are	  
few	  differences	  in	  residues	  between	  the	  two	  species.	  
Rat	  P2X3	  receptors	  are	  inhibited	  when	  a	  C-­‐terminal	  Src	  inhibitory	  kinase	  (Csk)	  phosphorylates	  
tyrosine-­‐393.	  However,	  human	  receptors	  have	  a	  phenylalanine	  at	  this	  residue	  position	  and	  tyrosine	  is	  
located	  at	  residue	  376.	  Since	  human	  receptors	  generate	  higher	  currents,	  slower	  desensitization,	  and	  
faster	  recovery	  than	  rat	  receptors,	  research	  suggests	  that	  P2X3	  activity	  results	  from	  this	  amino	  acid	  
alteration	  (Sundukova	  et	  al.,	  2012).	  
When	  rat	  P2X3	  receptors	  are	  mutagenized	  and	  tyrosine-­‐393	  is	  altered	  to	  a	  phenylalanine,	  there	  
are	  significantly	  larger	  currents	  than	  seen	  in	  the	  wild	  type.	  When	  phenylalanine-­‐376	  is	  changed	  to	  
tyrosine,	  there	  is	  no	  substantial	  difference	  in	  responses	  for	  the	  receptors	  (Sundukova	  et	  al.,	  2012).	  
Therefore,	  tyrosine-­‐393	  and	  its	  interaction	  with	  Csk	  must	  alter	  the	  P2X3	  response	  in	  rats	  (D’Arco	  et	  al.,	  
2009).	  
When	  human	  receptors	  are	  mutagenized	  and	  tyrosine-­‐376	  is	  mutated	  to	  phenylalanine,	  there	  is	  
a	  decreased	  current	  response	  when	  compared	  to	  the	  wild	  type.	  There	  is	  also	  a	  decrease	  when	  
phenylalanine-­‐393	  is	  changed	  to	  tyrosine,	  however,	  the	  decrease	  is	  not	  as	  great	  indicating	  that	  tyrosine-­‐
376	  is	  more	  vital	  in	  P2X3	  response.	  These	  results	  conclude	  the	  importance	  of	  the	  different	  tyrosine	  
residues	  found	  between	  humans	  and	  rats	  (Sundukova	  et	  al.,	  2012).	  
Figure	  2-­‐2	  below	  shows	  a	  schematic	  representation	  of	  the	  human	  and	  rat	  C-­‐terminal	  sequences	  
and	  the	  two	  mutants	  used	  in	  this	  project,	  ManRat	  and	  RatMan,	  previously	  characterized	  in	  published	  
work	  (Sundukova	  et	  al.,	  2012).	  
	  
Figure	  2-­‐2:	  Rat,	  Human,	  ManRat,	  and	  RatMan	  P2X3	  Sequences	  Compared	  
	  
RatMan	  consists	  of	  a	  rat	  P2X3	  receptor	  backbone	  with	  a	  Y393F	  single	  point	  mutation	  while	  
ManRat	  contains	  a	  human	  P2X3	  receptor	  backbone	  with	  a	  F393Y	  mutation.	  These	  mutants	  allow	  for	  
experimentation	  to	  observe	  the	  role	  of	  these	  C-­‐terminal	  residues	  in	  receptor	  function.	  
2.4	  CASK	  
Calcium/calmodulin-­‐dependent	  serine	  kinase	  (CASK)	  is	  a	  phosphorylating	  scaffold	  enzyme	  that	  is	  
capable	  of	  altering	  the	  expression	  and	  function	  of	  P2X3	  (Volonté	  &	  Burnstock,	  2013).	  Recombinant	  
expression	  of	  P2X3	  and	  CASK	  in	  human	  embryonic	  kidney	  (HEK)	  293T	  cells	  showed	  an	  increase	  in	  serine	  
phosphorylation	  on	  the	  receptor	  protein,	  which	  has	  been	  shown	  to	  upregulate	  expression.	  CASK	  knock-­‐
out	  (KO)	  mutants	  were	  also	  found	  to	  enhance	  P2X3	  expression,	  while	  silencing	  CASK	  resulted	  in	  
decreased	  expression.	  Because	  of	  this,	  CASK	  has	  shown	  to	  exercise	  control	  over	  P2X3	  receptors	  and	  may	  
be	  an	  intracellular	  target	  for	  studying	  purinergic	  signalling	  in	  nociceptors	  (Gnanasekaran	  et	  al.,	  2013).	  
The	  interaction	  is	  postulated	  to	  have	  a	  phosphorylating	  mechanism.	  CASK	  has	  a	  pseudokinase	  
domain	  suggested	  to	  phosphorylate	  neurexin	  (Mukherjee	  et	  al.,	  2008);	  however,	  no	  other	  CASK	  target	  
has	  been	  identified.	  Being	  a	  scaffold	  protein,	  CASK	  could	  interact	  with	  adaptor	  proteins	  that	  may	  contain	  
phosphorylating	  enzymes.	  This	  in	  turn	  extends	  the	  capabilities	  of	  CASK	  when	  it	  forms	  a	  complex	  with	  
other	  proteins.	  Preliminary	  binding	  experiments	  suggest	  that	  the	  N-­‐terminal	  P2X3	  domain	  is	  not	  
involved	  in	  the	  interaction.	  The	  interaction	  could	  be	  thus	  centralized	  at	  the	  intracellular	  C-­‐terminus.	  
CASK	  could	  modulate	  the	  activity	  of	  P2X3	  in	  health	  or	  disease,	  resulting	  in	  higher	  or	  lower	  receptor	  
opening	  efficiency.	  The	  postulated	  interaction	  between	  CASK	  and	  P2X3	  is	  illustrated	  below	  in	  Figure	  2-­‐3.	  
As	  the	  illustration	  suggests,	  CASK	  creates	  a	  complex	  with	  P2X3.	  When	  the	  channel	  opens,	  non-­‐specific	  
ions	  flow	  into	  the	  cell.	  The	  CASK/P2X3	  complex	  may	  then	  disassemble	  (Gnanasekeran	  et	  al.,	  2013),	  
suggesting	  that	  the	  interaction	  has	  a	  functional	  nature	  and	  is	  controlled	  by	  extracellular	  ATP.	  The	  
complex	  disassembly	  is	  also	  important	  to	  control	  effectors	  downstream	  in	  purinergic	  signaling	  
(Fabbretti,	  2013).	  
Also,	  there	  is	  the	  possibility	  for	  more	  protein-­‐protein	  interactions	  in	  this	  complex	  (Fabbretti,	  
2013;	  Volonté	  &	  Burnstock,	  2013).	  
	  
	  Figure	  2-­‐3:	  P2X3	  and	  CASK	  Interaction.	  The	  P2X3	  and	  CASK	  proteins	  are	  labeled.	  When	  ions,	  such	  as	  
calcium	  and	  sodium,	  flow	  through	  the	  P2X3	  receptor,	  the	  complex	  disassembles.	  
	  
To	  analyze	  the	  importance	  of	  CASK	  in	  the	  CNS,	  CASK	  KO	  and	  knock-­‐down	  mice	  were	  created,	  
and	  the	  CASK	  KO	  mice	  died	  within	  one	  day	  of	  birth.	  In	  the	  same	  study,	  CASK	  expression	  was	  knocked-­‐
down	  to	  about	  30	  percent	  and	  these	  mice	  showed	  less	  bodily	  growth	  yet	  sustained	  viability.	  Further	  
research	  examined	  that	  CASK	  was	  not	  necessary	  for	  evoked	  neurotransmitter	  release,	  but	  does	  play	  
some	  extraordinary	  role	  in	  modulating	  spontaneous	  release	  of	  neurotransmitters	  essential	  to	  maintain	  
the	  synaptic	  strength	  (Atasoy	  et	  al.,	  2007).	  Also,	  CASK	  mutants	  have	  been	  associated	  to	  diseases	  
determined	  in	  altered	  synaptic	  function,	  such	  as	  mental	  retardation	  (Hackett,	  2010).	  
2.5	  P2X3	  Antagonists	  
By	  targeting	  molecules	  involved	  in	  chronic	  pain,	  drug	  therapeutics	  can	  be	  configured	  to	  block	  
the	  pain	  pathways.	  The	  pharmaceutical	  industry	  is	  interested	  in	  providing	  small	  molecular	  antagonists.	  
These	  agents	  would	  be	  capable	  of	  blocking	  out	  pain	  signaling	  provoked	  through	  P2X3	  and	  other	  similar	  
ion	  channels	  (Ford,	  2012).	  
	   One	  company	  is	  specifically	  targeting	  the	  P2X3	  receptor	  and	  undergoing	  clinical	  trials.	  Afferent	  
Pharmaceuticals	  is	  exploring	  the	  practical	  use	  of	  controlling	  P2X3’s	  activity	  by	  developing	  novel	  
therapeutics	  to	  treat	  chronic	  pain	  and	  other	  painful	  diseases.	  In	  2011,	  they	  produced	  9	  different	  P2X3	  
antagonists	  that	  led	  to	  one	  compound	  that	  is	  currently	  in	  clinical	  studies	  with	  human	  patients	  to	  treat	  
osteoarthritis	  pain,	  chronic	  cough,	  and	  interstitial	  cystitis.	  Orally	  administered	  AF-­‐219	  will	  complete	  its	  
second	  phase	  of	  clinical	  trials	  in	  2014	  (“P2X3	  Antagonism”,	  2012).	   	  
3.	  Materials	  and	  Methods	  
Cell	  Culture	  and	  Transfection	  
Human	  embryonic	  kidney	  (HEK)	  293T	  cells	  were	  obtained	  from	  the	  ATCC	  (American	  Tissue	  
Culture	  Collection,	  Maryland).	  The	  cells	  were	  grown	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  
containing	  10%	  fetal	  bovine	  serum	  (FBS),	  2	  mM	  of	  L-­‐glutamate,	  and	  antibiotics	  (1X	  penicillin	  and	  1X	  
streptomycin).	  Cells	  were	  passaged	  once	  the	  cells	  were	  more	  than	  70%	  confluent.	  To	  passage	  the	  cells,	  
cells	  were	  incubated	  for	  5	  minutes	  in	  a	  solution	  containing	  0.025%	  Trypsin	  and	  0.01%	  EDTA	  in	  phosphate	  
buffer	  solution	  (PBS)	  to	  digest	  extracellular	  matrix	  and	  cell-­‐cell	  surface	  adhesion	  contacts.	  The	  
proteolytic	  digestion	  was	  blocked	  by	  DMEM,	  supplemented	  with	  10%	  FBS.	  Cells	  were	  recovered	  in	  a	  
pellet	  by	  centrifugation	  (5	  min).	  The	  supernatant	  was	  removed	  and	  a	  cell	  count	  was	  performed	  with	  a	  
hemocytometer.	  The	  number	  of	  cells	  was	  calculated	  with	  the	  following	  equation:	  
Cells/mL	  =	  (Live	  Cells	  *	  104)	  /	  (Number	  of	  Squares	  *	  Dilution	  factor)	  
	  
The	  desired	  number	  of	  cells	  was	  moved	  into	  a	  new	  flask	  containing	  new	  complete	  medium.	  
For	  the	  first	  half	  of	  the	  experiments,	  cells	  were	  plated	  in	  35	  mm	  Petri	  dishes	  and	  transfected	  
with	  the	  calcium/phosphate	  method	  (D’Arco	  et	  al.,	  2009)	  and	  0.5	  μL	  of	  each	  plasmid.	  The	  plasmids	  and	  
their	  concentrations	  are	  listed	  in	  Table	  1.	  
	  
	  
Table	  1:	  Plasmids	  and	  Their	  Concentrations	  used	  in	  Transfection	  Experiments.	  Concentrations	  were	  
measured	  with	  the	  Quanti-­‐iT	  dsDNA	  HS	  Assay	  kit	  (Q32851,	  Invitrogen)	  and	  samples	  were	  read	  in	  the	  
QubitTM	  fluorometer.	  
After	  calculating	  the	  plasmid	  concentrations	  and	  to	  obtain	  higher	  transfection	  efficiencies,	  the	  
transfection	  protocol	  was	  changed.	  Cells	  were	  washed	  with	  PBS	  and	  a	  mixture	  containing	  200	  μL	  of	  Opti-­‐
MEM	  media	  (containing	  minimal	  essential	  media,	  HEPES,	  sodium	  bicarbonate	  and	  supplemented	  with	  
hypoxanthine,	  thymidine,	  sodium	  pyruvate,	  L-­‐glutamine,	  and	  growth	  factors),	  a	  total	  of	  1	  μg	  of	  plasmid	  
DNA,	  and	  2	  μL	  of	  X-­‐tremeGene	  HP	  Transfection	  Reagent	  (365752001,	  Complete,	  Roche,	  Basel,	  
Switzerland)	  was	  added	  drop	  by	  drop	  to	  the	  petri	  dishes.	  The	  following	  plasmids,	  already	  present	  in	  the	  
lab	  (Gnanasekeran	  et	  al.,	  2013)	  were	  used:	  pcDNA3-­‐human	  P2X3	  (A.	  North,	  Sheffield,	  UK;	  NCBI	  
accession	  number:	  AAH74793),	  pcDNA3-­‐rat	  P2X3	  (A.	  North;	  NCBI	  accession	  number:	  CAA62594),	  
pcDNA3-­‐CASK	  (L.	  Tsai,	  Cambridge,	  MA,	  USA),	  pEGFP	  (Clontech,	  Mountain	  View,	  CA,	  USA),	  and	  pcDNA3	  
(Invitrogen	  Life	  Science,	  Carlsbad,	  CA,	  USA)	  as	  an	  empty	  vector.	  The	  plasmids	  (Figure	  3-­‐1)	  were	  verified	  
by	  agarose	  gel	  electrophoresis.	  
	  
	  
Figure	  3-­‐1:	  The	  pcDNA3	  plasmid	  with	  the	  cut	  site	  labeled	  for	  the	  wild-­‐type	  and	  mutant	  P2X3	  plasmids	  
and	  CASK	  plasmid.	  
Western	  Blotting	  
Transfected	  HEK	  293T	  cells	  were	  lysed	  in	  TNE	  buffer	  (1%	  Triton	  X-­‐100,	  10	  mM	  Tris-­‐HCl,	  pH	  7.5,	  
150	  mM	  NaCl,	  2mM	  EDTA),	  0.1M	  NaF,	  20	  mM	  orthovanadate,	  and	  a	  mixture	  of	  protease	  inhibitors	  
(Roche),	  scraped	  into	  Eppendorf	  tubes,	  homogenized	  with	  a	  syringe,	  and	  centrifuged	  for	  20	  minutes	  at	  
4°C.	  An	  aliquot	  from	  these	  samples	  were	  then	  mixed	  with	  bicinchoninic	  acid	  solution	  and	  4%	  copper	  
sulfate	  (Sigma)	  to	  determine	  the	  protein	  concentrations	  with	  a	  spectrophotometer	  (reading	  at	  562	  nm).	  
To	  increase	  efficiency	  for	  determining	  the	  protein	  concentrations,	  the	  Quanti-­‐iT	  dsDNA	  HS	  Assay	  kit	  
(Q32851,	  Invitrogen)	  was	  used	  and	  concentrations	  were	  determined	  by	  the	  Qubit™	  fluorometer.	  
From	  each	  sample	  lysate,	  proteins	  were	  diluted	  1:1	  with	  the	  loading	  dye	  buffer	  (Laemmli,	  1972).	  
Proteins	  were	  separated	  by	  electrophoresis	  at	  75V	  for	  20	  minutes,	  and	  then	  130V	  for	  approximately	  an	  
hour	  and	  a	  half.	  While	  the	  concentration	  of	  the	  stacking	  gel	  is	  constant	  at	  4%,	  the	  concentration	  of	  the	  
running	  gel	  is	  chosen	  depending	  on	  the	  predicted	  molecular	  weights	  of	  proteins	  to	  be	  separated,	  and	  
can	  range	  from	  6-­‐12%.	  
In	  our	  experiments,	  cell	  lysates	  were	  separated	  on	  8%	  SDS-­‐PAGE	  gels	  (running),	  containing	  40%	  
acrylamide-­‐bis,	  1.5M	  Tris	  pH	  8.8,	  10%	  SDS,	  10%	  ammonium	  persulfate	  (APS),	  and	  TEMED.	  The	  gel	  was	  
then	  transferred	  to	  a	  nitrocellulose	  membrane	  using	  Towbin’s	  transfer	  buffer	  (25	  mM	  Tris,	  0.2	  M	  
glycine,	  20%	  methanol	  in	  water)	  at	  100V	  for	  an	  hour.	  The	  membrane	  was	  stained	  with	  a	  Ponceau	  
solution	  (Sigma,	  Milan,	  Italy)	  to	  evaluate	  the	  transfer	  efficiency.	  The	  membrane	  was	  washed	  and	  
blocked	  in	  a	  5%	  milk	  solution	  with	  1X	  Tris-­‐Buffered	  Saline	  with	  0.1%	  Tween	  20	  (TBS-­‐T)	  on	  a	  shaker	  for	  an	  
hour.	  
The	  membrane	  was	  probed	  with	  the	  primary	  rabbit	  anti-­‐P2X3	  antibodies	  (0.8	  μg/mL,	  APR016,	  
Alomone,	  Jerusalem,	  Israel)	  and	  rabbit	  anti-­‐CASK	  antibodies	  (0.4	  μg/mL,	  10777,	  Santa	  Cruz	  
Biotechnology,	  Santa	  Cruz,	  CA,	  USA).	  The	  membrane	  was	  incubated	  with	  the	  secondary	  antibody,	  rabbit	  
HRP-­‐conjugated	  anti-­‐Ig	  (2	  μg/mL,	  A0545,	  Sigma).	  The	  anti-­‐P2X3	  antibody	  antigen	  corresponds	  to	  the	  
peptide	  (C)VEKQSTDSGAYSIGH,	  from	  a	  rat	  C-­‐terminus	  P2X3	  receptor	  region,	  and	  has	  been	  validated	  to	  
detect	  human,	  rat,	  and	  mouse	  P2X3	  receptors	  (Alomone;	  Sundukova	  et	  al.,	  2012).	  The	  signals	  from	  the	  
Western	  blot	  were	  detected	  by	  using	  the	  ImmobilonTM	  Western	  Chemiluminescent	  HRP	  Substrate	  
(Millipore,	  Billerica,	  USA)	  and	  images	  acquired	  using	  Kodak	  MM4000.	  
Co-­‐Immunoprecipitation	  
Cell	  lysates	  were	  prepared	  as	  previously	  described	  for	  the	  Western	  blot	  and	  protein	  
concentrations	  were	  determined	  by	  using	  a	  spectrophotometer.	  For	  immunoprecipitation,	  the	  protein	  
lysate	  samples	  were	  added	  to	  a	  solution	  containing	  PureProteome	  Protein	  A	  Magnetic	  Beads	  (Millipore)	  
and	  rabbit	  anti-­‐P2X3	  antibodies	  (0.4	  μg/mL,	  sc-­‐25694,	  Santa	  Cruz).	  The	  rabbit	  anti-­‐P2X3	  antibody	  
immunogen	  corresponds	  to	  the	  60	  aa	  peptide:	  
(C)LCDIILLNFLKGADQYKAKKFEEVNETTLKIAALTNPVYPSDQTTAEKQSTDSGAFSIGH	  from	  a	  human	  P2X3	  
receptor.	  It	  was	  designed	  to	  detect	  human,	  rat,	  and	  mouse	  P2X3	  receptors	  (Santa	  Cruz).	  
After	  rotation	  of	  the	  samples	  for	  an	  hour	  at	  4°C,	  the	  immune	  complexes	  were	  purified	  by	  
magnetic	  separation	  and	  a	  series	  of	  washing	  steps	  in	  1X	  TBS-­‐T.	  Samples	  were	  eluted	  from	  magnetic	  
beads	  by	  heating	  at	  95°C	  for	  10	  minutes	  with	  help	  of	  the	  magnet.	  Immunopurified	  protein	  samples	  were	  
then	  loaded	  onto	  a	  8%	  SDS-­‐PAGE	  polyacrylamide	  gel,	  transferred	  to	  nitrocellulose,	  and	  processed	  for	  
Western	  blotting	  as	  previously	  described.	  
Immunofluorescence	  
HEK	  293T	  cells	  grown	  on	  (untreated)	  glass	  coverslips	  were	  washed	  in	  PBS	  and	  fixed	  in	  4%	  
paraformaldehyde	  for	  20	  minutes	  at	  room	  temperature	  and	  blocked	  with	  5%	  BSA,	  1%	  FBS,	  and	  0.1%	  
Triton	  X-­‐100	  in	  PBS	  for	  an	  hour	  at	  room	  temperature.	  Cells	  were	  incubated	  for	  45	  minutes	  with	  rabbit	  
anti-­‐rat	  P2X3	  antibodies	  (4	  μg/mL,	  Alomone,	  Jerusalem,	  Israel)	  and	  anti-­‐CASK	  antibodies	  (10	  μg/mL,	  
Millipore,	  Milan,	  Italy)	  added	  to	  the	  blocking	  solution	  and	  then	  washed.	  The	  cells	  were	  then	  incubated	  
with	  secondary	  antibodies	  AlexaFluor	  488	  (4	  μg/mL,	  Invitrogen)	  and	  AlexaFluor	  594	  (4	  μg/mL,	  
Invitrogen).	  Nuclei	  were	  counterstained	  with	  4’,6-­‐Diamidino-­‐2-­‐phenylin-­‐dole	  (DAPI)	  (5	  μg/mL	  ,	  
Invitrogen).	  Samples	  were	  observed	  with	  the	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  images	  
were	  collected	  with	  Axiovision	  (Zeiss)	  software. 	  
4.	  Results	  
4.1	  Plasmid	  Analysis	  
	   An	  agarose	  gel	  electrophoresis	  was	  performed	  to	  verify	  the	  quality	  of	  the	  plasmids	  used	  in	  
subsequent	  experiments	  (Figure	  4-­‐1).	  
	  
Figure	  4-­‐1:	  Human	  and	  rat	  P2X3,	  CASK,	  GFP,	  and	  an	  empty	  vector’s	  plasmid	  DNA.	  Plasmids	  were	  
resolved	  on	  1%	  agarose	  gel,	  supplemented	  with	  ethidium	  bromide,	  and	  visualized	  under	  UV.	  Plasmids	  
were	  of	  expected	  size.	  
4.2	  Plasmid	  Expression	  
	   Initial	  experiments,	  including	  immunofluorescence,	  were	  performed	  to	  test	  the	  expression	  of	  
the	  P2X3	  receptor	  and	  CASK	  protein	  separately	  and	  together	  in	  transfected	  HEK	  cells.	  For	  
immunofluorescence,	  cells	  were	  transfected	  for	  24	  hours	  with	  plasmids	  containing	  different	  
combinations	  of	  the	  P2X3	  receptor	  and	  CASK	  cDNA.	  Human	  P2X3	  was	  transfected	  in	  two	  cell	  cultures:	  
one	  with	  co-­‐transfection	  of	  CASK	  and	  one	  without.	  The	  same	  was	  performed	  for	  rat	  P2X3.	  In	  addition,	  
controls	  were	  created	  and	  cells	  were	  transfected	  with	  CASK	  alone	  and	  an	  empty	  vector.	  The	  results	  of	  
this	  experiment	  showed	  that	  CASK	  co-­‐expresses	  and	  co-­‐localizes	  with	  human	  P2X3	  and	  rat	  P2X3	  in	  HEK	  
cells	  (Figures	  4-­‐2	  and	  4-­‐3).	  
	  Figure	  4-­‐2:	  Expression	  of	  human	  and	  rat	  P2X3	  receptor	  and	  CASK	  in	  HEK	  cells	  24	  hours	  after	  
transfection.	  Cells	  were	  transfected	  with	  a	  control	  plasmid	  (Empty),	  plasmid	  containing	  CASK,	  human	  
P2X3,	  human	  P2X3	  and	  CASK,	  rat	  P2X3,	  or	  rat	  P2X3	  and	  CASK.	  Both	  human	  and	  rat	  receptors	  were	  
detected	  by	  immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  
CASK	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  
(blue).	  Images	  were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  
Axiovision	  (Zeiss)	  software.	  Bar	  =	  50	  µm.	  
	  
Figure	  4-­‐3:	  Expression	  of	  human	  and	  rat	  P2X3	  receptor	  and	  CASK	  in	  HEK	  cells	  24	  hours	  after	  
transfection.	  Cells	  were	  transfected	  with	  a	  plasmid	  containing	  CASK,	  human	  P2X3,	  human	  P2X3	  and	  
CASK,	  rat	  P2X3,	  or	  rat	  P2X3	  and	  CASK.	  Both	  human	  and	  rat	  receptors	  were	  detected	  by	  
immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  CASK	  with	  
secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  (blue).	  Images	  
were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  Axiovision	  (Zeiss)	  
software.	  Bar	  =	  20	  µm.	  
P2X3	  signal	  intensity	  was	  strong	  for	  all	  human	  and	  rat	  P2X3	  transfections	  and	  CASK	  signal	  was	  
well	  represented	  in	  all	  CASK	  and	  P2X3/CASK	  transfections.	  DAPI	  staining	  tagged	  the	  DNA	  in	  each	  cell	  and	  
its	  signal	  was	  seen	  abundantly	  in	  the	  last	  column	  as	  a	  representation	  of	  all	  cells.	  A	  co-­‐localization	  of	  the	  
P2X3	  receptor	  and	  CASK	  was	  seen	  as	  yellow	  since	  both	  protein	  signals,	  red	  and	  green,	  overlapped	  each	  
other.	  
Transfection	  efficiencies	  were	  calculated	  for	  each	  transfection	  seen	  above	  in	  Figures	  4-­‐2	  and	  4-­‐3	  
(Figure	  4-­‐4).	  
	  
Figure	  4-­‐4:	  Transfection	  efficiency	  after	  24	  hours.	  Transfection	  efficiency	  was	  quantified	  for	  ten	  
different	  fields	  by	  dividing	  the	  number	  of	  cells	  expressing	  transfected	  plasmids	  by	  the	  total	  number	  of	  
cells	  stained	  with	  DAPI	  (n	  =	  10).	  
The	  rat	  P2X3	  single	  transfection	  had	  the	  greatest	  efficiency	  at	  11.88	  ±	  3.32%.	  The	  rat	  P2X3/CASK	  
sample	  also	  had	  a	  greater	  efficiency	  than	  either	  human	  P2X3	  sample.	  CASK	  was	  expressed	  in	  all	  cells	  
transfected	  with	  the	  CASK	  plasmid	  and	  its	  efficiency	  average	  was	  5.85%.	  
An	  immunofluorescence	  experiment	  was	  repeated	  48	  hours	  after	  transfection	  (Figures	  4-­‐5	  and	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Figure	  4-­‐5:	  Expression	  of	  human	  and	  rat	  P2X3	  receptor	  and	  CASK	  in	  HEK	  cells	  48	  hours	  after	  
transfection.	  Cells	  were	  transfected	  with	  a	  control	  plasmid	  (Empty),	  plasmid	  containing	  CASK,	  human	  
P2X3,	  human	  P2X3	  and	  CASK,	  rat	  P2X3,	  or	  rat	  P2X3	  and	  CASK.	  Both	  human	  and	  rat	  receptors	  were	  
detected	  by	  immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  
CASK	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  
(blue).	  Images	  were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  
Axiovision	  (Zeiss)	  software.	  Bar	  =	  50	  µm.	  
 
	  
Figure	  4-­‐6:	  Expression	  of	  human	  and	  rat	  P2X3	  receptor	  and	  CASK	  in	  HEK	  cells	  48	  hours	  after	  
transfection.	  Cells	  were	  transfected	  with	  a	  plasmid	  containing	  CASK,	  human	  P2X3,	  human	  P2X3	  and	  
CASK,	  rat	  P2X3,	  or	  rat	  P2X3	  and	  CASK.	  Both	  human	  and	  rat	  receptors	  were	  detected	  by	  
immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  CASK	  with	  
secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  (blue).	  Images	  
were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  Axiovision	  (Zeiss)	  
software.	  Bar	  =	  20	  µm.	  
	   Similar	  to	  Figures	  4-­‐2	  and	  4-­‐3,	  P2X3	  signals	  were	  strongly	  observed	  in	  all	  human	  and	  rat	  P2X3	  
transfections	  after	  48	  hours.	  CASK	  signals	  were	  evident	  in	  all	  CASK	  transfections,	  with	  a	  better	  
observation	  of	  this	  in	  Figure	  4-­‐6.	  Co-­‐localization	  between	  the	  P2X3	  receptor	  and	  CASK	  was	  visible	  in	  the	  
merge	  column,	  represented	  by	  yellow	  since	  both	  P2X3	  and	  CASK	  signals,	  red	  and	  green,	  overlapped	  each	  
other.	  Transfection	  efficiencies	  were	  calculated	  again	  for	  the	  cells	  seen	  in	  Figures	  4-­‐5	  and	  4-­‐6	  (Figure	  4-­‐
7).	  
	  
Figure	  4-­‐7:	  Transfection	  efficiency	  after	  48	  hours.	  Transfection	  efficiency	  was	  quantified	  for	  ten	  
different	  fields	  by	  dividing	  the	  number	  of	  cells	  expressing	  transfected	  plasmids	  by	  the	  total	  number	  of	  
cells	  stained	  with	  DAPI	  (n	  =	  10).	  
	   The	  post-­‐48	  hours	  samples	  had	  similar	  efficiencies	  to	  each	  other	  for	  both	  proteins.	  Both	  P2X3	  
receptors	  were	  successfully	  transfected	  into	  an	  average	  of	  2.5%	  of	  the	  HEK	  cells.	  The	  CASK	  protein	  was	  
successfully	  observed	  in	  around	  2%	  of	  all	  HEK	  cells.	  No	  outliers	  were	  found.	  
	   Another	  immunofluorescence	  experiment	  was	  performed	  to	  check	  co-­‐expression	  of	  wild-­‐type	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ManRat,	  as	  previously	  described	  in	  the	  Background	  section.	  RatMan	  is	  a	  rat	  P2X3	  receptor	  with	  a	  single	  
point	  mutagenesis	  at	  residue	  393,	  mutating	  a	  tyrosine	  into	  a	  phenylalanine	  (Y393F).	  ManRat	  is	  a	  human	  




Figure	  4-­‐8:	  Comparative	  expression	  of	  wild-­‐type	  and	  mutated	  P2X3	  receptors	  and	  CASK	  in	  HEK	  cells.	  
Cells	  were	  transfected	  with	  a	  control	  plasmid	  (Empty),	  plasmid	  containing	  human	  P2X3	  and	  CASK,	  rat	  
P2X3	  and	  CASK,	  RatMan	  P2X3	  and	  CASK,	  or	  ManRat	  P2X3	  and	  CASK.	  All	  receptors	  were	  detected	  by	  
immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  CASK	  with	  
secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  (blue).	  Images	  
were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  Axiovision	  (Zeiss)	  
software.	  Bar	  =	  50	  µm.	  
 
	  
Figure	  4-­‐9:	  Comparative	  expression	  of	  wild-­‐type	  and	  mutated	  P2X3	  receptors	  and	  CASK	  in	  HEK	  cells.	  
Cells	  were	  transfected	  with	  a	  control	  plasmid	  (Empty),	  plasmid	  containing	  human	  P2X3	  and	  CASK,	  rat	  
P2X3	  and	  CASK,	  RatMan	  P2X3	  and	  CASK,	  or	  ManRat	  P2X3	  and	  CASK.	  All	  receptors	  were	  detected	  by	  
immunocytochemistry	  with	  secondary	  antibodies	  conjugated	  to	  AlexaFluor	  488	  (green)	  and	  CASK	  with	  
secondary	  antibodies	  conjugated	  to	  AlexaFluor	  594	  (red).	  Nuclei	  were	  labeled	  with	  DAPI	  (blue).	  Images	  
were	  acquired	  on	  a	  Zeiss	  Axio	  Observer.Z1	  inverted	  microscope	  and	  processed	  using	  Axiovision	  (Zeiss)	  
software.	  Bar	  =	  20	  µm.	  
	   Transfection	  efficiencies	  were	  calculated	  for	  the	  human,	  rat,	  RatMan,	  and	  ManRat	  P2X3	  
receptors	  and	  CASK	  co-­‐transfections	  (Figure	  4-­‐10).	  
	  
Figure	  4-­‐10:	  Comparison	  of	  transfection	  efficiencies	  for	  the	  human	  and	  rat	  wild-­‐type	  P2X3	  receptors	  
and	  mutant	  receptors,	  ManRat	  and	  RatMan,	  when	  co-­‐expressed	  with	  CASK.	  Transfection	  efficiency	  
was	  quantified	  for	  ten	  different	  fields	  by	  dividing	  the	  number	  of	  cells	  expressing	  transfected	  plasmids	  by	  
the	  total	  number	  of	  cells	  stained	  with	  DAPI	  (n	  =	  4).	  
	   The	  P2X3	  and	  CASK	  proteins	  seemed	  to	  transfect	  at	  similar	  efficiencies	  in	  each	  sample.	  Besides	  
the	  RatMan	  P2X3	  receptor	  at	  12.32	  ±	  4.60%	  efficiency,	  the	  other	  samples	  showed	  lower	  transfection	  
efficiencies.	  Both	  ManRat	  and	  rat	  P2X3	  transfected	  cells	  had	  the	  lowest	  efficiencies	  at	  2.08	  ±	  0.59%	  and	  
2.28	  ±	  0.43%,	  respectively.	  
Western	  blots	  were	  performed	  to	  further	  characterize	  plasmid	  expression.	  Resulting	  bands	  of	  
both	  proteins,	  P2X3	  and	  CASK,	  confirmed	  their	  presence	  and	  expression.	  A	  western	  blot	  was	  performed	  
with	  HEK	  cells	  transfected	  with	  human,	  rat,	  RatMan,	  and	  ManRat	  P2X3	  sequences	  and	  CASK.	  An	  empty	  

























	  Figure	  4-­‐11	  –	  Western	  blot	  showing	  the	  expression	  of	  human,	  rat,	  RatMan,	  and	  ManRat	  P2X3	  
receptors	  and	  CASK	  in	  HEK	  cells.	  The	  left	  four	  lanes	  represent	  samples	  of	  HEK	  cells	  transfected	  with	  
plasmids	  containing	  human,	  rat,	  RatMan,	  or	  ManRat	  P2X3	  receptors	  and	  CASK.	  The	  right	  four	  lanes	  are	  
samples	  of	  HEK	  cells	  transfected	  with	  human	  or	  rat	  P2X3	  plasmids,	  with	  and	  without	  a	  CASK	  plasmid.	  
After	  running	  the	  samples	  on	  8%	  SDS-­‐PAGE	  gels,	  the	  membrane	  was	  probed	  with	  primary	  rabbit	  anti-­‐
P2X3	  (Alomone)	  and	  anti-­‐CASK	  (Santa	  Cruz)	  antibodies.	  Rabbit	  HRP-­‐conjugated	  anti-­‐Ig	  (Sigma)	  secondary	  
antibody	  was	  then	  added.	  Bands	  were	  detected	  using	  ImmobilonTM	  Western	  Chemiluminescent	  HRP	  
Substrate	  (Millipore)	  and	  images	  were	  taken	  with	  Kodak	  MM4000.	  Actin	  was	  used	  as	  a	  loading	  control.	  
	   To	  provide	  a	  raw	  quantification	  approach,	  band	  intensities	  for	  each	  sample	  represented	  in	  
Figure	  4-­‐11	  were	  normalized	  against	  their	  respective	  actin	  band	  and	  then	  compared	  to	  the	  control,	  or	  
empty	  vector	  (Figure	  4-­‐12).	  
	  Figure	  4-­‐12:	  CASK	  and	  P2X3	  Band	  Intensities	  Quantified	  from	  Figure	  4-­‐11.	  Raw	  intensity	  values,	  
expressed	  as	  absolute	  units,	  for	  P2X3,	  CASK,	  and	  actin	  were	  calculated	  by	  ImageJ	  software.	  The	  P2X3	  
and	  CASK	  values	  were	  then	  normalized	  against	  each	  sample’s	  respective	  actin	  value.	  Both	  sets	  of	  data	  
were	  compared	  to	  the	  control,	  or	  empty	  vector.	  The	  control	  is	  represented	  as	  the	  dashed	  line	  at	  a	  value	  
of	  1.	  
	   For	  the	  CASK	  values	  graph,	  all	  samples	  with	  a	  CASK	  transfection	  had	  more	  expression	  than	  the	  
control.	  Those	  without	  a	  CASK	  plasmid,	  human	  and	  rat	  P2X3,	  had	  CASK	  expression	  levels	  equal	  to	  or	  just	  
above	  the	  control.	  For	  the	  P2X3	  values	  graph,	  all	  samples	  expressed	  more	  P2X3	  protein	  than	  the	  control.	  
The	  human	  and	  rat	  P2X3	  single	  transfections	  had	  exceptionally	  high	  expression	  at	  values	  of	  24.01	  and	  
64.72	  units,	  respectively.	  
	   To	  standardize	  the	  protein	  lysates	  and	  Western	  blot	  procedure,	  multiple	  Western	  blots	  were	  
performed.	  The	  intensity	  values	  were	  calculated	  for	  samples	  run	  in	  all	  Western	  blots	  performed	  and	  the	  
values	  were	  normalized	  against	  each	  respective	  actin	  band	  (Figure	  4-­‐13).	  
	  Figure	  4-­‐13:	  CASK	  and	  P2X3	  Band	  Intensities	  Quantified	  from	  All	  Western	  Blots.	  Raw	  intensity	  values	  
for	  P2X3,	  CASK,	  and	  actin	  were	  calculated	  by	  Image	  J	  software.	  The	  P2X3	  and	  CASK	  values	  were	  then	  
normalized	  against	  each	  sample’s	  respective	  actin	  value.	  Standard	  deviation	  was	  calculated	  and	  is	  
shown	  by	  error	  bars	  (n	  =	  6	  for	  human	  P2X3/CASK	  and	  rat	  P2X3/CASK;	  n	  =	  5	  for	  empty;	  n	  =	  3	  for	  
ManRat/CASK,	  RatMan/CASK,	  human	  P2X3,	  and	  rat	  P2X3).	  
	   For	  the	  CASK	  values,	  all	  samples	  had	  similar	  intensity	  values.	  The	  human	  P2X3	  and	  empty	  
plasmid	  transfections	  have	  the	  lowest	  CASK	  expression	  levels.	  For	  P2X3	  values,	  the	  empty	  vector	  had	  the	  
lowest	  expression	  level	  and	  the	  rat	  P2X3	  sample	  had	  significantly	  higher	  P2X3	  expression.	  
4.3	  Interaction	  between	  P2X3	  and	  CASK	  
Rat	  P2X3	  and	  CASK	  have	  been	  previously	  shown	  to	  pull	  down	  together	  with	  an	  anti-­‐P2X3	  
antibody,	  meaning	  they	  are	  part	  of	  the	  same	  molecular	  complex.	  Co-­‐immunoprecipitation	  was	  
performed	  to	  test	  whether	  human	  P2X3	  receptors	  and	  CASK	  proteins	  also	  pull	  down	  together,	  in	  order	  
to	  provide	  a	  rationale	  for	  future	  biomedical	  applications.	  
The	  co-­‐immunoprecipitation	  was	  performed	  with	  HEK	  cells	  transfected	  with	  human	  or	  rat	  P2X3	  
and	  CASK	  plasmids.	  An	  empty	  vector	  served	  as	  a	  control	  (Figure	  4-­‐14).	  Anti-­‐P2X3	  antibodies	  attached	  to	  
the	  P2X3	  receptor,	  thereby	  pulling	  down	  proteins	  attached	  to	  the	  receptor.	  
	  Figure	  4-­‐14:	  Pull	  down	  of	  CASK	  with	  human	  and	  rat	  P2X3	  receptors.	  Cells	  were	  transfected	  with	  a	  
control	  plasmid	  (Empty	  Vector),	  plasmid	  containing	  rat	  P2X3	  and	  CASK,	  or	  human	  P2X3	  and	  CASK.	  Co-­‐
transfections	  were	  done	  in	  duplicate	  to	  test	  reproducibility.	  Rabbit	  anti-­‐P2X3	  (Santa	  Cruz)	  antibodies	  
were	  used	  to	  pull	  down	  the	  molecular	  complex.	  After	  the	  samples	  were	  run	  on	  8%	  SDS-­‐PAGE	  gels,	  the	  
membrane	  was	  probed	  with	  primary	  rabbit	  anti-­‐P2X3	  (Alomone)	  and	  anti-­‐CASK	  (Santa	  Cruz)	  antibodies.	  
Rabbit	  HRP-­‐conjugated	  anti-­‐Ig	  (Sigma)	  secondary	  antibody	  was	  then	  added.	  Bands	  were	  detected	  using	  
ImmobilonTM	  Western	  Chemiluminescent	  HRP	  Substrate	  (Millipore)	  and	  images	  were	  taken	  with	  Kodak	  
MM4000.	  
	   CASK	  protein	  was	  pulled	  down	  in	  all	  samples	  except	  the	  empty	  plasmid.	  Less	  expression	  was	  
observed	  for	  the	  second	  rat	  P2X3/CASK	  transfection.	  The	  P2X3	  receptor	  had	  a	  very	  low	  expression	  level.	  
A	  band	  was	  observed	  in	  the	  first	  human	  P2X3/CASK	  sample	  around	  55	  kDa.	  No	  actin	  signals	  appeared,	  as	  
expected.	  
4.4	  Identification	  of	  Residues	  Responsible	  for	  Interaction	  between	  P2X3	  and	  
CASK	  
A	  co-­‐immunoprecipitation	  was	  performed	  for	  both	  wild-­‐type	  and	  mutant	  P2X3	  receptors	  to	  
analyze	  if	  mutations	  at	  residues	  376	  and	  393	  were	  involved	  in	  the	  CASK	  interaction	  (Figure	  4-­‐15).	  Anti-­‐
P2X3	  antibodies	  attached	  to	  the	  human,	  rat,	  and	  mutant	  P2X3	  receptors,	  pulling	  down	  proteins	  
associated	  to	  the	  receptors.	  
	  Figure	  4-­‐15:	  Pull	  down	  of	  CASK	  with	  human,	  rat,	  ManRat,	  and	  RatMan	  P2X3	  receptors.	  Cells	  were	  
transfected	  with	  a	  control	  plasmid	  (Empty	  Vector),	  plasmid	  containing	  rat	  P2X3	  and	  CASK,	  human	  P2X3	  
and	  CASK,	  ManRat	  P2X3	  and	  CASK,	  or	  RatMan	  P2X3	  and	  CASK.	  Rabbit	  anti-­‐P2X3	  (Santa	  Cruz)	  antibodies	  
were	  used	  to	  pull	  down	  the	  molecular	  complex.	  After	  the	  samples	  were	  run	  on	  8%	  SDS-­‐PAGE	  gels,	  the	  
membrane	  was	  probed	  with	  primary	  rabbit	  anti-­‐P2X3	  (Alomone)	  and	  anti-­‐CASK	  (Santa	  Cruz)	  antibodies.	  
Rabbit	  HRP-­‐conjugated	  anti-­‐Ig	  (Sigma)	  secondary	  antibody	  was	  then	  added.	  Bands	  were	  detected	  using	  
ImmobilonTM	  Western	  Chemiluminescent	  HRP	  Substrate	  (Millipore)	  and	  images	  were	  taken	  with	  Kodak	  
MM4000.	  
	   CASK	  protein	  signals	  appear	  in	  each	  lane,	  with	  a	  lower	  expression	  for	  the	  empty	  vector	  sample.	  
Strong	  P2X3	  expression	  is	  observed	  for	  both	  mutants,	  ManRat	  and	  RatMan.	  Very	  weak	  P2X3	  expression	  
is	  seen	  for	  the	  rat	  and	  human	  P2X3/CASK	  samples.	  Actin	  signals	  were	  not	  detected,	  as	  expected.	  
	   	  
5.	  Discussion	  
The	  overall	  goal	  for	  this	  project	  was	  to	  further	  understand	  the	  relationship	  between	  the	  P2X3	  
receptor	  and	  the	  CASK	  protein.	  Through	  the	  use	  of	  different	  methods,	  the	  group	  was	  able	  to	  transfect	  
and	  measure	  the	  overexpression	  of	  CASK	  protein	  and	  visualize	  its	  co-­‐localization	  with	  P2X3	  receptors	  in	  
microscopy	  and	  Western	  blot	  experiments.	  In	  addition,	  it	  was	  also	  determined	  that	  the	  human	  P2X3	  
receptor	  is	  in	  the	  same	  molecular	  complex	  as	  CASK,	  which	  was	  previously	  seen	  for	  the	  rat	  P2X3	  
receptor.	  
	   Through	  the	  use	  of	  immunofluorescence	  (Figures	  4-­‐2,	  4-­‐3,	  4-­‐5,	  &	  4-­‐6),	  it	  was	  confirmed	  that	  
P2X3	  and	  CASK	  plasmids	  are	  expressed	  in	  HEK	  cells,	  and	  the	  proteins	  co-­‐localize	  in	  the	  same	  cells.	  
Although	  this	  is	  not	  sufficient	  to	  conclude	  that	  these	  molecules	  are	  a	  part	  of	  the	  same	  complex,	  it	  proves	  
that	  they	  could	  function	  in	  close	  proximity.	  The	  images	  suggest	  the	  proteins	  are	  co-­‐localized	  in	  or	  
around	  the	  cell	  membrane,	  or	  at	  least	  in	  the	  same	  cellular	  compartment.	  This	  experiment	  also	  proved	  
that	  the	  cells	  were	  correctly	  transfected	  with	  the	  confirmed	  plasmids	  (Figure	  4-­‐1).	  
When	  comparing	  samples	  post	  24	  and	  48	  hour	  transfections	  (Figure	  4-­‐4	  and	  Figure	  4-­‐7	  
respectively),	  a	  clear	  time-­‐dependent	  change	  in	  P2X3	  expression	  was	  observed,	  which	  could	  be	  due	  to	  
the	  cytotoxicity	  of	  P2X3	  in	  the	  presence	  of	  a	  high	  concentration	  of	  ATP	  from	  high	  density	  cultures	  
(Apicella	  et	  al.,	  2012).	  Some	  efforts	  have	  been	  made	  to	  titrate	  the	  plasmid	  concentrations	  before	  
reading	  spectrophotometer	  measurements,	  in	  order	  to	  render	  them	  comparable.	  Also,	  the	  transfection	  
efficiency	  is	  the	  result	  of	  a	  balance	  between	  the	  P2X3	  receptor	  expression,	  the	  time	  after	  transfection,	  
and	  the	  concentration	  of	  extracellular	  ATP	  present	  (Apicella	  et	  al.,	  2012).	  
The	  expression	  efficiency	  for	  the	  rat	  P2X3	  samples	  after	  24	  hours	  was	  significantly	  greater	  than	  
the	  human	  P2X3	  transfections.	  This	  could	  be	  due	  to	  the	  higher	  plasmid	  concentration	  used	  for	  rat	  P2X3	  
during	  the	  transfection.	  However,	  previous	  research	  (Sundukova	  et	  al.,	  2012)	  suggests	  that	  human	  P2X3	  
receptor	  expression	  is	  significantly	  greater	  than	  the	  rat	  receptor	  when	  transfected	  with	  equal	  amounts	  
of	  the	  plasmids.	  Therefore,	  transfecting	  with	  more	  rat	  P2X3	  plasmid	  should	  not	  have	  shown	  such	  a	  
considerably	  greater	  expression	  level	  over	  the	  human	  receptor.	  
Similarly,	  the	  immunofluorescence	  experiments	  that	  used	  cells	  transfected	  with	  mutants	  
(Figures	  4-­‐8	  &	  4-­‐9)	  showed	  correct	  plasmid	  expression	  for	  P2X3	  and	  CASK.	  However,	  for	  the	  empty	  
vector,	  a	  small	  amount	  of	  green	  fluorescence	  appears	  in	  the	  20x	  magnification	  and	  a	  large	  amount	  of	  
green	  fluorescence	  appears	  in	  the	  100x	  magnification.	  This	  could	  be	  attributed	  to	  potential	  background	  
noise	  that	  could	  have	  been	  picked	  up	  during	  the	  imaging	  process	  because	  there	  was	  a	  lack	  of	  manual	  
control	  of	  auto-­‐exposure	  mode.	  Also,	  it	  should	  be	  noted	  that	  for	  the	  ManRat	  P2X3/CASK	  sample,	  the	  
merge	  of	  both	  signals	  seems	  to	  appear	  co-­‐localized	  inside	  the	  cell	  (Figure	  4-­‐9).	  The	  proteins	  seemed	  to	  
co-­‐localize	  around	  the	  cell	  in	  all	  other	  samples.	  
In	  addition,	  the	  transfection	  efficiency	  for	  the	  RatMan	  mutant	  was	  more	  than	  double	  the	  human	  
P2X3	  efficiency,	  which	  was	  the	  second	  highest	  value.	  The	  comparison,	  however,	  is	  not	  simple	  since	  
microscopy	  quantifies	  expression	  at	  single	  cellular	  level,	  while	  biochemistry	  data	  report	  the	  entire	  
lysates.	  Therefore,	  it	  is	  also	  suggested	  that	  there	  may	  have	  been	  problems	  with	  the	  transfection	  rather	  
than	  the	  immunofluorescence.	  Importantly,	  the	  transfection	  protocol	  and	  plasmid	  preparations	  were	  
changed	  in	  order	  to	  improve	  the	  receptor	  expression	  yield,	  rendering	  it	  very	  complex	  to	  compare	  initial	  
microscopy	  experiments	  with	  Western	  blot	  data.	  Finally,	  it	  was	  suspected	  to	  obtain	  higher	  efficiency	  
values	  in	  all	  transfected	  samples	  because	  of	  the	  protocol	  change	  to	  use	  the	  X-­‐treme	  Gene	  protocol,	  
which	  should	  have	  greatly	  increased	  the	  results.	  Unfortunately,	  this	  did	  not	  occur,	  and	  lower	  
transfection	  efficiencies	  were	  observed	  instead	  (Figure	  4-­‐10),	  most	  likely	  due	  to	  the	  cytotoxic	  potential	  
of	  overexpressed	  P2X3	  receptors	  (Apicella	  et	  al.,	  2012).	  
	   To	  further	  analyze	  the	  plasmid	  expression	  of	  the	  HEK	  cells,	  a	  Western	  blot	  of	  both	  the	  wild-­‐type	  
samples	  and	  the	  mutants	  showed	  correct	  transfection	  of	  proteins	  of	  the	  expected	  molecular	  size	  (Figure	  
4-­‐11).	  For	  the	  samples	  that	  were	  transfected	  with	  CASK,	  the	  bands’	  intensities	  (Figure	  4-­‐12)	  were	  higher	  
than	  the	  empty	  vector,	  which	  proves	  that	  more	  protein	  was	  being	  expressed	  compared	  to	  the	  empty	  
vector	  and	  the	  human	  and	  rat	  P2X3,	  which	  only	  contained	  endogenous	  CASK.	  For	  P2X3	  expression,	  all	  
samples	  showed	  higher	  intensities	  as	  compared	  to	  the	  control.	  The	  rat	  and	  human	  P2X3	  samples	  that	  
were	  not	  co-­‐transfected	  with	  CASK	  show	  much	  greater	  expression	  of	  P2X3	  than	  those	  that	  were	  co-­‐
transfected	  with	  CASK,	  suggesting	  that	  CASK	  controls	  the	  P2X3	  receptor	  stability	  or	  that	  it	  influences	  
P2X3-­‐mediated	  cytotoxicity.	  These	  results	  contradict	  research	  showing	  that	  CASK	  stabilizes	  the	  P2X3	  
receptor,	  which	  would	  yield	  higher	  expression	  (Gnanasekaran	  et	  al.,	  2013).	  A	  double	  transfection	  of	  the	  
cells	  could	  have	  inhibited	  the	  other	  expression	  levels,	  while	  the	  singular	  transfection	  did	  not.	  However,	  
there	  is	  no	  explicit	  data	  proving	  this	  theory.	  
Also,	  the	  stain	  for	  β-­‐actin	  shows	  two	  bands	  that	  were	  stained	  rather	  than	  one.	  This	  could	  be	  a	  
result	  of	  the	  quality	  of	  the	  lysates	  and	  some	  protease	  activity	  that	  could	  have	  been	  active	  throughout	  
the	  samples.	  Lastly,	  Figure	  4-­‐13	  shows	  that	  throughout	  all	  of	  the	  Western	  blots	  that	  were	  performed,	  
not	  much	  difference	  was	  shown	  in	  CASK	  values,	  while	  there	  was	  a	  variety	  in	  the	  P2X3	  values.	  The	  empty	  
vector	  overall	  contained	  the	  least	  amount	  of	  P2X3,	  which	  was	  expected	  because	  it	  served	  as	  a	  negative	  
control,	  while	  the	  rat	  P2X3	  values	  were	  extremely	  higher	  than	  the	  others.	  This	  was	  due	  to	  the	  high	  
variability	  between	  different	  experiments	  that	  showed	  high	  expression	  levels	  in	  one	  of	  the	  Western	  blot	  
values,	  which	  skewed	  the	  overall	  average	  for	  the	  other	  Western	  blot	  values.	  Because	  the	  original	  
Western	  blot	  experiments	  were	  loaded	  with	  different	  plasmid	  concentrations,	  the	  data	  from	  these	  
experiments	  were	  extremely	  diverse,	  which	  caused	  the	  error	  bars	  to	  be	  large	  in	  the	  figure.	  	  
	   Through	  the	  use	  of	  co-­‐immunoprecipitation,	  an	  anti-­‐P2X3	  antibody	  was	  used	  to	  test	  if	  the	  
human	  P2X3	  receptor	  would	  pull	  down	  with	  the	  CASK	  protein,	  which	  was	  previously	  noted	  with	  the	  rat	  
P2X3	  receptor.	  As	  seen	  in	  Figure	  4-­‐14,	  CASK	  shows	  similar	  band	  intensities	  in	  the	  transfected	  cells,	  
except	  for	  one	  of	  the	  rat	  P2X3	  samples,	  which	  could	  have	  been	  due	  to	  a	  decreased	  concentration	  in	  the	  
cell	  lysate.	  Unfortunately,	  the	  P2X3	  receptor	  did	  not	  appear,	  which	  may	  have	  been	  due	  to	  P2X3	  
degradation.	  However,	  since	  the	  structure	  of	  the	  P2X3	  receptor	  is	  complex,	  the	  purification	  of	  these	  
proteins	  is	  not	  easy	  because	  they	  are	  highly	  embedded	  in	  the	  membranes.	  While	  CASK	  is	  a	  soluble	  
protein	  and	  external	  to	  the	  membranes,	  P2X3	  receptors	  could	  be	  more	  resistant	  to	  extraction,	  which	  
could	  explain	  why	  little	  was	  resolved	  in	  the	  SDS-­‐PAGE.	  Nevertheless,	  because	  CASK	  is	  present,	  this	  
indirectly	  indicates	  that	  the	  P2X3	  receptor	  must	  have	  pulled	  down	  the	  CASK	  protein	  because	  it	  was	  
directly	  connected	  to	  the	  anti-­‐P2X3	  antibody	  and	  magnetic	  bead	  complex.	  Although	  it	  is	  unknown	  
whether	  CASK	  and	  P2X3	  are	  directly	  attached,	  it	  can	  be	  concluded	  that	  P2X3	  receptors	  from	  both	  human	  
and	  rat	  origin	  are	  a	  part	  of	  the	  same	  molecular	  complex	  containing	  CASK.	  The	  membrane	  was	  stained	  
for	  β-­‐actin	  in	  addition	  to	  serve	  as	  a	  loading	  control;	  however,	  β-­‐actin	  was	  not	  identified	  since	  it	  is	  not	  
associated	  with	  the	  P2X3/CASK	  complex,	  which	  provided	  a	  specificity	  control.	  
	   For	  the	  co-­‐immunoprecipitation	  that	  involved	  the	  mutant	  P2X3	  plasmids	  (Figure	  4-­‐15),	  CASK	  
expression	  is	  similar	  for	  both	  mutant	  and	  wild-­‐type	  samples,	  which	  indicated	  that	  it	  cannot	  be	  inferred	  
which	  residue	  plays	  a	  more	  influential	  role	  in	  the	  interaction.	  Ideally,	  there	  would	  have	  been	  varying	  
CASK	  expression	  levels	  between	  the	  different	  conformations,	  which	  would	  have	  highlighted	  one	  residue	  
over	  another.	  Also,	  CASK	  expression	  appeared	  in	  the	  empty	  vector	  sample,	  although	  endogenous	  CASK	  
could	  not	  have	  been	  present	  without	  the	  aid	  of	  P2X3.	  This	  expression	  could	  be	  explained	  by	  human	  
error	  in	  the	  protocol.	  Furthermore,	  P2X3	  showed	  a	  strong	  intensity	  for	  both	  of	  the	  mutants,	  including	  	  
duplex	  bands	  for	  each,	  but	  also	  showed	  a	  weak	  intensity	  for	  the	  wild	  types.	  All	  human	  and	  rat	  P2X3	  and	  
CASK	  co-­‐transfection	  samples	  in	  both	  co-­‐immunoprecipitation	  experiments	  showed	  low	  expression	  
levels,	  which	  could	  be	  due	  to	  the	  degradation	  of	  the	  P2X3	  receptor	  in	  the	  cell	  lysates.	  	  
	   Overall,	  the	  experiments	  confirmed	  the	  co-­‐expression	  and	  co-­‐localization	  of	  the	  P2X3	  receptor	  
and	  CASK	  protein.	  It	  confirmed	  a	  complex	  between	  human	  P2X3	  and	  CASK,	  which	  had	  not	  been	  
previously	  discovered.	  Also,	  HEK	  cells	  were	  shown	  to	  stably	  overexpress	  the	  P2X3	  receptor	  and	  CASK	  
protein,	  which	  can	  now	  be	  used	  as	  a	  model	  cell	  line	  to	  further	  study	  their	  interactions.	  
	   	  
6.	  Recommendations	  
The	  experiments	  performed	  were	  useful	  in	  visualizing	  the	  co-­‐localization	  of	  the	  P2X3	  receptor	  
and	  the	  CASK	  protein,	  as	  well	  as	  proving	  that	  these	  molecules	  interact	  directly	  or	  indirectly	  in	  the	  same	  
complex.	  To	  further	  understand	  this	  complex,	  it	  would	  be	  beneficial	  to	  perform	  silver	  staining	  and	  
proteomic	  experiments	  to	  determine	  other	  potential	  molecules	  involved.	  This	  could	  lead	  to	  
understanding	  more	  about	  the	  chronic	  pain	  pathway	  and	  how	  pain	  signals	  could	  be	  blocked	  or	  altered.	  
In	  addition,	  it	  would	  also	  be	  interesting	  to	  look	  at	  P2X3	  activity	  by	  using	  siRNA	  or	  a	  similar	  small	  
RNA	  interfering	  technique	  to	  terminate	  possible	  adaptor	  proteins	  or	  kinases.	  This	  would	  leave	  P2X3	  and	  
CASK	  interacting	  exclusively,	  and	  the	  consequences	  of	  these	  interfering	  RNAs	  could	  be	  observed.	  Knock-­‐
down	  experiments	  could	  also	  modulate	  the	  P2X3	  and	  CASK	  complex	  to	  explore	  its	  functionality.	  Also,	  
the	  CASK	  role	  in	  the	  P2X3	  receptor	  biology	  is	  also	  poorly	  known,	  even	  though	  there	  has	  been	  published	  
data	  that	  report	  their	  role	  in	  receptor	  stability,	  mobility	  and	  trafficking	  to/from	  the	  surface	  membrane.	  
The	  expression	  of	  both	  CASK	  and	  P2X3	  from	  human	  origin	  in	  a	  human	  context	  (i.e.	  HEK	  cells)	  can	  open	  
new	  interesting	  avenues	  in	  the	  study	  of	  the	  interactions	  and	  modulations	  of	  the	  P2X3	  receptors.	  
	   HEK	  cells	  in	  culture	  are	  prone	  to	  secrete	  high	  concentrations	  of	  ATP,	  even	  after	  mechanical	  
stress.	  It	  is	  known	  that	  ATP	  activates	  and	  opens	  P2X3	  receptor	  channels,	  which	  could	  induce	  long-­‐lasting	  
cytotoxicity	  (Apicella	  et	  al.,	  2013),	  as	  well	  as	  influence	  the	  CASK/P2X3	  interaction	  state	  (Gnanasekeran	  et	  
al.,	  2013).	  Further	  experiments,	  eventually	  done	  in	  the	  presence	  of	  selective	  inhibitory	  drugs	  (receptor	  
antagonists)	  are	  necessary	  to	  understand	  the	  time	  course	  of	  these	  events.	  Furthermore,	  it	  is	  now	  clear	  
that	  single	  point	  mutations	  can	  change	  the	  overall	  stability	  of	  the	  receptor	  and	  their	  functional	  
properties,	  and	  this	  could	  be	  further	  explored	  because	  human	  and	  rat	  receptors	  show	  98%	  homology.	  
Currently,	  nothing	  is	  known	  regarding	  differences	  in	  trafficking	  and	  stability	  of	  human	  receptors	  and	  
how	  this	  is	  influenced	  by	  CASK.	  
Phosphorylation	  between	  P2X3	  and	  CASK	  could	  also	  be	  researched.	  CASK	  is	  named	  for	  its	  serine	  
kinase	  activity,	  and	  while	  the	  protein	  interaction	  with	  P2X3	  is	  unknown,	  it	  is	  possible	  to	  determine	  the	  
phosphorylation	  activity	  of	  CASK	  on	  the	  receptor.	  CASK	  could	  assemble	  a	  complex	  of	  adaptor	  proteins	  or	  
kinases	  capable	  of	  altering	  the	  phosphorylation	  state	  of	  P2X3.	  Also,	  using	  anti-­‐phosphoserine	  antibodies	  
to	  bind	  to	  the	  C-­‐terminal	  intracellular	  domain	  could	  reveal	  further	  information.	  
	   If	  the	  functionality	  of	  the	  P2X3/CASK	  complex	  is	  known,	  then	  pharmaceutical	  companies	  can	  
begin	  to	  create	  drugs	  that	  can	  target	  this	  complex,	  which	  could	  stop	  the	  pain	  signal	  at	  the	  pre-­‐synapse	  in	  
the	  dorsal	  horn,	  rather	  than	  allowing	  the	  pain	  signal	  to	  travel	  to	  the	  brain	  and	  create	  a	  sensory	  
response.	  Although	  this	  could	  only	  be	  administered	  in	  specific	  cases	  due	  to	  the	  potential	  hazards	  of	  pain	  
desensitization,	  further	  uses	  for	  this	  type	  of	  medication	  could	  be	  explored.	  
	   The	  use	  of	  FRET,	  or	  Förster	  resonance	  energy	  transfer,	  could	  help	  with	  the	  drug	  development	  
process,	  as	  well	  as	  provide	  more	  information	  on	  the	  P2X3	  and	  CASK	  interaction.	  This	  technique	  exposes	  
a	  fluorescent	  tag	  to	  light	  which	  produces	  a	  color	  and	  signal.	  However,	  if	  two	  fluorescent	  tags	  were	  close	  
in	  proximity,	  then	  the	  colors	  and	  signals	  would	  be	  different.	  Signals	  would	  fluoresce	  a	  different	  color	  due	  
to	  resonance	  energy	  transfer	  from	  the	  donor	  fluorophore	  to	  the	  other	  proximal	  acceptor	  fluorophore.	  If	  
P2X3	  was	  tagged	  with	  a	  fluorescent	  tag,	  such	  as	  CFP,	  and	  CASK	  was	  tagged	  with	  a	  different	  fluorescent	  
tag,	  such	  as	  YFP,	  then	  a	  direct	  interaction	  would	  fluoresce	  yellow	  due	  to	  YFP.	  If	  the	  interaction	  were	  
indirect,	  then	  it	  is	  likely	  that	  the	  fluorescence	  would	  take	  a	  cyan	  color,	  due	  to	  CFP.	  Since	  the	  P2X3	  and	  
CASK	  interaction	  is	  dynamic	  and	  transient,	  this	  method	  could	  be	  applied	  to	  test	  different	  compounds	  
added	  to	  a	  solution	  containing	  the	  P2X3/CASK	  complex	  to	  observe	  whether	  the	  complex	  disassembles	  or	  
not,	  based	  on	  the	  signals	  given	  by	  the	  fluorophores.	  Then	  conclusions	  could	  be	  inferred	  as	  to	  the	  
efficiency	  of	  each	  drug	  to	  alter	  or	  inhibit	  the	  pain	  signal,	  leading	  to	  the	  discovery	  of	  new	  pain	  
medications.	  
	   In	  conclusion,	  our	  work	  explored	  the	  requirements	  of	  the	  CASK	  and	  P2X3	  interaction,	  confirming	  
the	  validity	  of	  previously	  discovered	  mechanisms	  in	  a	  human	  context.	  This	  supports	  the	  importance	  of	  
further	  investments	  to	  design	  biomedical	  research	  applications	  based	  on	  fluorescence	  biotechnologies	  
or	  synthetic	  biology	  based	  on	  this	  interaction	  mechanism.	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